Breaking News Instant updates and real-time market news.

KNSA

Kiniksa

$15.08

0.7 (4.87%)

07:45
05/13/19
05/13
07:45
05/13/19
07:45

Kiniksa presents KPL-716 data at the Society for Investigative Dermatology

Kiniksa announced that it presented clinical and preclinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta, or OSMRss, the shared receptor subunit for interleukin-31, or IL-31, and oncostatin M, or OSM signaling. The data were included in oral and poster presentations at the Society for Investigative Dermatology. Data from the adjunctive therapy period of Kiniksa's Phase 1a/1b clinical trial of single-dose KPL-716 7.5 mg/kg intravenous, or IV, in subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus versus placebo IV showed a sustained anti-pruritic effect of OSMRss inhibition through at least week 6. The data reinforce and extend the previously-reported findings from the Phase 1a/1b monotherapy period, which provided evidence of target engagement and an early signal of efficacy in reducing pruritus and disease severity. Data from Kiniksa's longitudinal observational study in prurigo nodularis, or LOTUS-PN, suggest that the OSMRss axis may play a role in the pathogenesis of prurigo nodularis given its prevalent expression in lesional prurigo nodularis. IL-31 messenger ribonucleic acid, or mRNA, was expressed in approximately two-thirds of lesional biopsies from prurigo nodularis patients with Worst-Itch Numeric Rating Scale of 7 compared to one-tenth in healthy volunteers. Additionally, lesional biopsies from prurigo nodularis patients contained mononuclear cells expressing OSM, OSMRss, IL-31 and IL-31Ra protein compared with non-lesional biopsies. OSM is involved in Type 2 T helper, or TH2, inflammation, epidermal integrity and fibrosis. Data highlight the therapeutic potential of KPL-716, through the inhibition of OSM activity, in TH2 mediated diseases discrete from inhibition of IL-31. Further, the data show induction of MCP-1 and mRNA by OSM in both cell types tested and significant attenuation by KPL-716 of the cellular MCP-1 response to OSM and the synergistic response to OSM and interleukin-4, or IL-4. Importantly, these data showed that OSM synergizes with IL-4 and interleukin-13, or IL-13, and that leukemia inhibitory factor and IL-31 do not. KPL-716 data from a preclinical model exhibited dose- and time-dependent anti-pruritic effects. Pharmacokinetic and pharmacodynamic correlation established an efficacious concentration range of 5-8.5 microg/ml in cynomolgus monkeys, at or above which KPL-716 provided protection from pruritus induced by supra-physiologic challenges of IL-31. The results with single dose KPL-716 IV were corroborated with repeat-dosed KPL-716 subcutaneous in various dosing regimens and were predictive of the reduction in pruritus observed in the Phase 1a/1b clinical trial of single-dose KPL-716 7.5 mg/kg IV in subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritis.

  • 13

    May

  • 14

    May

KNSA Kiniksa
$15.08

0.7 (4.87%)

06/18/18
WEDB
06/18/18
INITIATION
Target $31
WEDB
Outperform
Kiniksa initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Kiniksa with an Outperform rating and $31 price target as he believes shares are undervalued given the company's initial focus on late-stage, clinically de-risked assets for rare diseases with limited competition, as is the case for rilonacept in recurrent pericarditis and mavrilimumab in giant cell arteritis.
06/18/18
JMPS
06/18/18
INITIATION
Target $33
JMPS
Outperform
Kiniksa initiated with an Outperform at JMP Securities
Before the open, JMP Securities analyst Liisa Bayko started coverage of Kiniksa with an Outperform rating and $33 price target, stating that the company has put together a clinical-stage portfolio of three unique medicines that are "well spaced at different stages of development" in an "impressively short period of time."
09/17/18
JMPS
09/17/18
NO CHANGE
Target $44
JMPS
Outperform
Kiniksa price target raised to $44 from $33 at JMP Securities
JMP Securities analyst Liisa Bayko increased her probability of success estimate for KPL-716 to 10% from 5% after Kiniksa presented data from a single-dose Phase 1 study at the EADV Congress. The early stage data met the primary safety endpoint and showed early signals of efficacy across multiple pruritus endpoints, said Bayko. Given the higher odds for success of KPL-716, she raised her price target on Kiniksa shares to $44 and keeps an Outperform rating on the stock.
03/11/19
LEHM
03/11/19
INITIATION
Target $26
LEHM
Overweight
Kiniksa initiated with an Overweight at Barclays
Barclays analyst Geoff Meacham started Kiniksa Pharmaceuticals with an Overweight rating and $26 price target.

TODAY'S FREE FLY STORIES

STAG

STAG Industrial

$29.71

-0.055 (-0.18%)

07:14
09/18/19
09/18
07:14
09/18/19
07:14
Conference/Events
STAG Industrial management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NBY

NovaBay

$0.53

0.0089 (1.72%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Initiation
NovaBay initiated  »

NovaBay initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

LECO

Lincoln Electric

$89.48

0.38 (0.43%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSC

Scansource

$30.64

-0.6 (-1.92%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Conference/Events
Scansource management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Hot Stocks
BeyondSpring sees sufficient cash to submit NDAs in China for Plinabulin »

As of June 30, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Earnings
BeyondSpring reports Q2 EPS (32c), one est. (27c) »

"During the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SBAC

SBA Communications

$252.94

6.55 (2.66%)

07:10
09/18/19
09/18
07:10
09/18/19
07:10
Conference/Events
SBA Communications management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:09
09/18/19
09/18
07:09
09/18/19
07:09
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

WLTW

Willis Towers Watson

$198.60

3.52 (1.80%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Hot Stocks
Willis Research Network partners with Mitiga Solutions on aviation initiative »

The Willis Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PM

Philip Morris

$71.98

-0.54 (-0.74%)

, MO

Altria Group

$41.31

-0.1 (-0.24%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Philip Morris, Altria Group analyst commentary  »

Philip Morris, Altria…

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$150.43

0.86 (0.57%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUBI

Rubicon Project

$9.41

0.24 (2.62%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Conference/Events
Rubicon Project management to meet with B. Riley FBR »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 30

    Sep

GIS

General Mills

$55.03

0.48 (0.88%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Earnings
General Mills backs FY20 adj. EPS growth guidance of 3%-5% »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

PLUG

Plug Power

$2.72

-0.04 (-1.45%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Hot Stocks
Plug Power announces hydrogen supply agreement with United Hydrogen »

Plug Power and United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

REXR

Rexford Industrial

$44.50

0.01 (0.02%)

07:07
09/18/19
09/18
07:07
09/18/19
07:07
Hot Stocks
Rexford Industrial acquires industrial park for $66.2M »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTS

Akoustis

$7.90

0.1 (1.28%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Downgrade
Akoustis rating change  »

Akoustis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 12

    Nov

BK

BNY Mellon

$46.35

-0.4 (-0.86%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Hot Stocks
BNY Mellon announces strategic alliance with Bloomberg »

The Bank of New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

, ENB

Enbridge

$35.27

0.1 (0.28%)

07:06
09/18/19
09/18
07:06
09/18/19
07:06
Hot Stocks
NextDecade, Enbridge announce MOU to develop pipelines in South Texas »

NextDecade (NEXT) and…

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

ENB

Enbridge

$35.27

0.1 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCI

Navigant Consulting

$27.93

0.05 (0.18%)

07:05
09/18/19
09/18
07:05
09/18/19
07:05
Conference/Events
Navigant Consulting management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 10

    Oct

PLUG

Plug Power

$2.72

-0.04 (-1.45%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
Plug Power announces five-year plan targeting $1B of revenue by 2024 »

Plug Power has rolled out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

QUIK

QuickLogic

$0.38

0.0025 (0.66%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
QuickLogic, Airoha announce Bluetooth collaboration »

QuickLogic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GIS

General Mills

$55.03

0.48 (0.88%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Earnings
General Mills reports Q1 adj. EPS 79c, consensus 77c »

Reports Q1 revenue $4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

OII

Oceaneering

$14.80

-0.79 (-5.07%)

, BHGE

Baker Hughes

$23.37

-0.43 (-1.81%)

07:04
09/18/19
09/18
07:04
09/18/19
07:04
Hot Stocks
Oceaneering awarded contracts to supply subsea umbilicals by Baker Hughes »

Oceaneering (OII) has…

OII

Oceaneering

$14.80

-0.79 (-5.07%)

BHGE

Baker Hughes

$23.37

-0.43 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPW

Medical Properties Trust

$19.04

0.22 (1.17%)

07:03
09/18/19
09/18
07:03
09/18/19
07:03
Conference/Events
Medical Properties Trust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.